logo

Trovagene Inc. (TROV)



Trade TROV now with
  Date
  Headline
3/5/2018 8:16:51 AM Trovagene:First Patient Completes Cycle 1 Of Treatment With PCM-075 In Combination With Low Dose Cytarabine In AML Trial
2/6/2018 8:19:34 AM Trovagene Completes Cycle-One Dosing In First Patient Enrolled In Its Phase 1b/2 Clinical Trial Of PCM-075
12/15/2017 6:04:53 AM Trovagene Reports Pricing Of Public Offering Of 15 Mln Shares Of Common Stock
12/14/2017 8:14:30 AM Trovagene Submits Protocol For Phase 2 Clinical Trial Of PCM-075 Plus Abiraterone Acetate To FDA For Review
10/9/2017 8:03:42 AM FDA Grants Orphan Drug Designation To Trovagene's PLK1 Inhibitor, PCM-075, For Treatment Of AML
8/9/2017 4:30:45 PM Trovagene Q2 Loss/share $0.26 Vs. Loss $0.34 Year Ago
7/27/2017 8:10:32 AM Trovagene Says FDA Accepted Its IND Application For PCM-075, A Polo-like Kinase 1 Inhibitor
7/12/2017 8:04:17 AM Trovagene Announces Agreement With Novogene For NextCollect In China
7/6/2017 8:05:32 AM Trovagene Engages PRA Health Sciences To Conduct Phase 1b/2 Trial Of PCM-075
6/27/2017 8:05:06 AM Trovagene Announces Submission Of Investigational NDA To Initiate Phase 1b/2 Trial Of PCM-075 For Acute Myeloid Leukemia
6/22/2017 8:05:26 AM Trovagene Announces Agreement With Global Biopharma Company To Utilize Trovera CtDNA Tests And Services In Cancer Trials
6/12/2017 8:05:53 AM Trovagene Agrees With AstraZeneca To Utilize Trovera CtDNA Test And Services In Prospective Biomarker Study
3/15/2017 4:15:28 PM Trovagene Q4 Loss/share $0.34 Vs. Loss $0.26 Year Ago
10/4/2016 6:04:50 AM Pancreatic Cancer Action Network Selects Trovagene As The Liquid Biopsy Provider To Participate In Precision Promise